General [[side effect]]s of NSAAs, including nilutamide, include [[gynecomastia]] (40–80%), [[mastodynia|breast pain/tenderness]], [[hot flash]]es (67%), [[depression (mood)|depression]], [[fatigue (medical)|fatigue]], [[sexual dysfunction]] (including loss of [[libido]] and [[erectile dysfunction]]), decreased [[muscle]] mass, and decreased [[bone]] mass with an associated increase in [[bone fracture|fracture]]s.<ref name="Dart2004">{{cite book|author=Richard C. Dart|title=Medical Toxicology|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA521|year=2004|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-2845-4|pages=521–}}</ref><ref name="MDMD2008">{{cite book|author1=Lisa M DeAngelis MD|author2=Jerome B Posner MD|title=Neurologic Complications of Cancer|url=https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479|date=12 September 2008|publisher=Oxford University Press, USA|isbn=978-0-19-971055-3|pages=479–}}</ref><ref name="Lehne2013">{{cite book|author=Richard A. Lehne|title=Pharmacology for Nursing Care|url=https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297|year=2013|publisher=Elsevier Health Sciences|isbn=1-4377-3582-7|pages=1297–}}</ref> Also, [[nausea]] (24–27%), [[vomiting]], [[constipation]] (20%), and [[insomnia]] (16%) may occur with nilutamide.

 


 
Relative to other NSAAs, nilutamide has been uniquely associated with mild and reversible [[visual disturbance]]s (31–58%) including delayed ocular adaptation to darkness and impaired [[color vision]],<ref name="Becker2001">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=1196–}}</ref> a [[disulfiram]]-like<ref name="Dart2004" /> [[drinking alcohol|alcohol]] [[drug intolerance|intolerance]] (19%), [[interstitial pneumonitis]] (0.77–2.4%)<ref name="Gulley2011">{{cite book|author=James Leonard Gulley|title=Prostate Cancer|url=https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81|year=2011|publisher=Demos Medical Publishing|isbn=978-1-935281-91-7|pages=81–}}</ref><ref name="CamusIII2010">{{cite book|author1=Phillipe Camus|author2=Edward C Rosenow III|title=Drug-induced and Iatrogenic Respiratory Disease|url=https://books.google.com/books?id=QlJsBgAAQBAJ&pg=PA235|date=29 October 2010|publisher=CRC Press|isbn=978-1-4441-2869-7|pages=235–}}</ref><ref name="Held-Warmkessel2006">{{cite book|author=Jeanne Held-Warmkessel|title=Contemporary Issues in Prostate Cancer: A Nursing Perspective|url=https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA257|year=2006|publisher=Jones & Bartlett Learning|isbn=978-0-7637-3075-8|pages=257–}}</ref> (which can result in [[dyspnea]] (1%) as a secondary effect and can progress to [[pulmonary fibrosis]]),<ref name="WeinKavoussi2011">{{cite book|author1=Alan J. Wein|author2=Louis R. Kavoussi|author3=Andrew C. Novick |author4=Alan W. Partin |author5=Craig A. Peters |title=Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set|url=https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939|date=25 August 2011|publisher=Elsevier Health Sciences|isbn=978-1-4160-6911-9|pages=2939–}}</ref> and [[hepatitis]] (1%), and has a higher incidence of nausea and vomiting compared to other NSAAs.<ref name="DenisGriffiths1999" /><ref name="Chang2005">{{cite book|author=Chawnshang Chang|title=Prostate Cancer: Basic Mechanisms and Therapeutic Approaches|url=https://books.google.com/books?id=4xQAr3Uh8EUC&pg=PA11|date=1 January 2005|publisher=World Scientific|isbn=978-981-256-920-2|pages=11–}}</ref><ref name="Lehne2013" /><ref name="RamonDenis2007">{{cite book|author1=J. Ramon|author2=L.J. Denis|title=Prostate Cancer|url=https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA229|date=5 June 2007|publisher=Springer Science & Business Media|isbn=978-3-540-40901-4|pages=229–}}</ref> The incidence of interstitial pneumonitis with nilutamide has been found to be much higher in [[Japanese people|Japanese]] patients (12.6%), warranting particular caution in [[Asian people|Asian]] individuals.<ref name="Mahler1996">{{cite journal|last1=Mahler|first1=Charles|title=A Review of the Clinical Studies with Nilutamide|year=1996|pages=105–111|doi=10.1007/978-3-642-45745-6_10|quote=Akaza had to prematurely terminate a nilutamide study in Japan as 12.6% of his patients developed interstitial lung disease [4]. This complication has been mainly observed in Japan and much less in other trials worldwide.}}</ref><ref name="Micromedex2003">{{cite book|author=Micromedex|title=USP DI 2003: Drug Information for Healthcare Professionals|url=https://books.google.com/books?id=zEzWtsVl-KgC|date=1 January 2003|publisher=Thomson Micromedex|isbn=978-1-56363-429-1|pages=220–224}}</ref> There is a case report of simultaneous liver and lung toxicity in a nilutamide-treated patient.<ref name="pmid1580304">{{cite journal | vauthors = Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, Labrie F | title = Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report | journal = Am. J. Med. | volume = 92 | issue = 5 | pages = 563–6 | year = 1992 | pmid = 1580304 | doi = 10.1016/0002-9343(92)90756-2| url = }}</ref>

 


 
There is also a risk of [[hepatoxicity]] with nilutamide, though occurrence is very rare and the risk is significantly less than with flutamide.<ref name="JordanFurr2010">{{cite book|author1=Virgil Craig Jordan|author2=B. J. A. Furr|title=Hormone Therapy in Breast and Prostate Cancer|url=https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA356|date=5 February 2010|publisher=Springer Science & Business Media|isbn=978-1-59259-152-7|pages=356–}}</ref><ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA150|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=150–}}</ref> The incidence of abnormal [[liver function tests]] (e.g., [[elevated transaminases|elevated liver enzyme]]s) is 2–3% with nilutamide, relative to 42–62% for flutamide.<ref name="Jafri2014">{{cite journal|last1=Jafri|first1=Syed-Mohammed R.|title=Bicalutamide-induced hepatotoxicity: A rare adverse effect|journal=American Journal of Case Reports|volume=15|year=2014|pages=266–270|issn=1941-5923|doi=10.12659/AJCR.890679|pmid=24967002|pmc=4068966}}</ref><ref name="CRAIGFurr2010" /> [[Fulminant hepatic failure]] has been reported for nilutamide, with fatal outcome.<ref name="CRAIGFurr2010" /><ref name="Aronson2011">{{cite book|author=J. K. Aronson|title=Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions|url=https://books.google.com/books?id=zegpAgEt3CcC&pg=PA874|year=2011|publisher=Elsevier|isbn=978-0-444-53741-6|pages=874–}}</ref><ref name="pmid8977826">{{cite journal | vauthors = Marty F, Godart D, Doermann F, Mérillon H | title = [Fatal fulminating hepatitis caused by nilutamide. A new case] | language = French | journal = Gastroenterol. Clin. Biol. | volume = 20 | issue = 8–9 | pages = 710–1 | year = 1996 | pmid = 8977826 | doi = | url = }}</ref><ref name="MerwatKabbani2008">{{cite journal|last1=Merwat|first1=Shehzad N.|last2=Kabbani|first2=Wareef|last3=Adler|first3=Douglas G.|title=Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity|journal=Digestive Diseases and Sciences|volume=54|issue=4|year=2008|pages=910–913|issn=0163-2116|doi=10.1007/s10620-008-0406-8|quote=In addition, nilutamide is noted to exhibit mitochondrial toxicity by inhibiting complex I activity of the mitochondrial respiratory chain leading to the impairment of ATP formation and the biosynthesis of glutathione, thereby possibly predisposing the liver to toxicity [13].}}</ref> Similarly to flutamide, nilutamide exhibits [[mitochondria]]l [[toxicity]] in [[hepatocyte]]s by inhibiting [[Electron transport chain#Complex I|respiratory complex I]] ([[NADH:ubiquinone reductase (H+-translocating)|NADH ubiquinone oxidoreductase]]) (though not [[Electron transport chain#Mitochondrial redox carriers|respiratory complexes II, III, or IV]]) in the [[electron transport chain]], resulting in reduced [[adenosine triphosphate|ATP]] and [[glutathione]] production and thus decreased hepatocyte survival.<ref name="MerwatKabbani2008" /><ref name="pmid8035313">{{cite journal | vauthors = Berson A, Schmets L, Fisch C, Fau D, Wolf C, Fromenty B, Deschamps D, Pessayre D | title = Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen | journal = J. Pharmacol. Exp. Ther. | volume = 270 | issue = 1 | pages = 167–76 | year = 1994 | pmid = 8035313 | doi = | url = }}</ref><ref name="CoeJia2007">{{cite journal|last1=Coe|first1=Kevin J.|last2=Jia|first2=Yankai|last3=Ho|first3=Han Kiat|last4=Rademacher|first4=Peter|last5=Bammler|first5=Theo K.|last6=Beyer|first6=Richard P.|last7=Farin|first7=Frederico M.|last8=Woodke|first8=Libby|last9=Plymate|first9=Stephen R.|last10=Fausto|first10=Nelson|last11=Nelson|first11=Sidney D.|title=Comparison of the Cytotoxicity of the Nitroaromatic Drug Flutamide to Its Cyano Analogue in the Hepatocyte Cell Line TAMH: Evidence for Complex I Inhibition and Mitochondrial Dysfunction Using Toxicogenomic Screening|journal=Chemical Research in Toxicology|volume=20|issue=9|year=2007|pages=1277–1290|issn=0893-228X|doi=10.1021/tx7001349|pmid=17702527|pmc=2802183}}</ref> The [[nitro compound|nitro]] [[functional group|group]] of nilutamide has been theorized to be involved in both its hepatotoxicity and its [[pulmonary toxicity]].<ref name="CoeJia2007"/><ref name="BoelsterliHo2006">{{cite journal|last1=Boelsterli|first1=Urs|last2=Ho|first2=Han|last3=Zhou|first3=Shufeng|last4=Yeow Leow|first4=Koon|title=Bioactivation and Hepatotoxicity of Nitroaromatic Drugs|journal=Current Drug Metabolism|volume=7|issue=7|year=2006|pages=715–727|issn=1389-2002|doi=10.2174/138920006778520606|pmid=17073576}}</ref>

 

